Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
MENS
Jyong Biotech Ltd.
Jyong Biotech Ltd. (MENS) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.2
/ 5.0
C
Value
C+
Factor Score
2.5
/ 5.0
Growth
C+
Factor Score
2.5
/ 5.0
Profitability
D-
Factor Score
0.8
/ 5.0
Momentum
C
Factor Score
2.4
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
N/A
EV / EBITDA
-56.7
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-16.8%
Price Return 12M
-95.9%
Catalyst Signal
0.00
Market Cap
$127.7M
TTM Revenue
N/A
Price / Sales
N/A
ROE
N/A
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C+ (2.5) | D- (0.8) | C (2.4) | C+ (2.6) | C (2.2) |
| 2026-11-06 | C+ (2.5) | C+ (2.5) | D- (0.8) | C (2.4) | C+ (2.7) | C (2.2) |
| 2026-10-30 | C+ (2.5) | C+ (2.5) | D- (0.8) | C (2.2) | C+ (2.7) | C- (2.1) |
| 2026-10-23 | C+ (2.5) | C+ (2.5) | D- (0.8) | C- (1.9) | C+ (2.6) | C- (2.1) |
| 2026-10-16 | C+ (2.5) | C+ (2.5) | D- (0.8) | C- (2.0) | C+ (2.6) | C- (2.1) |
Page
1
of
4